News & Views

  • National Platforms Boost Singapore's Drug Development Efforts
    At the Launch Ceremony of Experimental Drug Development Centre. From left, Mr Lim Chuan Poh, Chairman, SFA; Mr Frederick Chew, CEO, A*STAR; Dr Damian O'Connell, CEO, EDDC; Mr Heng Swee Keat, Deputy Prime Minister And Minister For Finance; Ms Chan Lai Fung, Chairman, A*STAR and PS (NRD); Dr William Chin, Member, A*STAR Board, and Chairman, EDDC Governing Board; and Prof Tan Chorh Chuan, Chief Health Scientist, MOH.

National Platforms Boost Singapore's Drug Development Efforts

Jul 22 2019 Read 341 Times

The nation's drug development efforts have been given additional momentum with the introduction of two new platforms, and a grant scheme for drug discovery and development.

These national platforms aim to bridge the 'valley of death' between basic science research and pharmaceutical enterprises. They will also serve to catalyse collaboration across industry, research institutes, academia, and the hospitals; as well as nurture a strong pool of scientific talent for Singapore's biomedical ecosystem.

These announcements were made during the opening ceremony of the Experimental Drug Development Centre (EDDC) in Biopolis, officiated by Mr Heng Swee Keat, Deputy Prime Minister and Minister for Finance, and Chairman of the National Research Foundation (NRF).

EDDC is a national platform for drug discovery and development to channel high potential drug candidates toward realising commercial outcomes for Singapore, as well as clinical outcomes that will benefit Singaporeans. EDDC integrates A*STAR's Experimental Therapeutics Centre (ETC), the clinical development unit known as Drug Discovery and Development (D3), and the Experimental Biotherapeutics Centre (EBC).

Also launched, the Target Translation Consortium (TTC) brings together A*STAR, Duke-NUS Medical School, Lee Kong Chian School of Medicine, Nanyang Technological University, National Healthcare Group, National University of Singapore, National University Health System, and SingHealth. Helmed by EDDC, this new TTC coordinates early-stage drug discovery efforts across academia, healthcare institutions, and government agencies. This collaborative approach is an important competitive edge for Singapore's biomedical ecosystem amidst an increasingly sophisticated drug discovery and development space.

To complement these two new platforms, the Singapore Therapeutics Development Review (STDR) grant scheme was also announced. STDR consolidates three separate schemes by A*STAR, the National Health Innovation Centre Singapore (NHIC), as well as the Singapore-MIT Alliance for Research and Technology (SMART); into a new grant that funds early-stage projects up to S$750,000. It combines the expertise and resources of all three organisations, streamlining the assessment and feedback process for promising drug discovery and development projects.
 

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment




Digital Edition

Labmate UK & Ireland September 2019

September 2019

Articles Finding an easy, cost-effective way to break into new markets Exploring safe and intelligent multi-application liquid nitrogen cooling via auto-fill technology Characterisation o...

View all digital editions

Events

Analytica Anacon India & IndiaLabExpo

Sep 19 2019 Hyderabad, India

16th Confocal Raman Imaging Symposium

Sep 23 2019 Ulm Germany

Analitica Latin America

Sep 24 2019 Sao Paulo, Brazil

Pharma Asia

Sep 24 2019 Karachi, Pakistan

ILMAC

Sep 24 2019 Basel, Switzerland

View all events